UNIVERZITETNI KLINICNI CENTER MARIBOR — Clinical Trial Site

28 Registered trials

11 Currently recruiting

Organisation

UNIVERZITETNI KLINICNI CENTER MARIBOR

Location

Maribor, Slovenia

Identifier

ORG-100039023

Address

Ljubljanska Ulica 5, 2000, Slovenia

Departments

2203: Department of Neurological Diseases
3501: Division of Internal medicine, Department of Nephrology
3701: Department of Neurological Diseases
4601: Division of Internal Medicine, Department of Nephrology
8112: Neurology
Anaesthesiology, Intensive care and Pain Management
Department of Rheumatology
Department of gynaecological oncology
Department of gynecological and breast oncology
Department of Neurologic Diseases
Department of neurology
Department of Oncology
Department of Rheumatology
Intensive care
Klinika za interno medicino, Oddelek za gastroenterologijo
N/A
Neurology
Neurology Clinic
Oddelek za kozne in spolne bolezni

Clinical trials at this site (28)

Search interface

A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-01-07
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting

2025-520825-19-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 5 2025-12-16
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Refractory Focal Onset Epilepsy 4 2024-10-10
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f… Recruiting

2024-510892-40-00 Acute myocardial infarction complicated by cardiogenic 6 2024-02-29
EPO-TRAUMA Recruiting

2023-506081-31-00 Traumatic Injury 5 2022-03-29
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended

2023-508690-92-00 IgA Nephropathy 11 2021-09-20
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17